Cancer Research
Excerpt from the Press Release: SAN DIEGO, July 2, 2025 /PRNewswire/ — A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinicians monitor treatment response. Study Highlights Clinical Impact Current standards for monitoring lymphoma…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 2, 2025 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today presented new clinical data from the ongoing STARt-001 Phase 1/2 trial of Invikafusp alfa during an oral session at the European Society of Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025.…
Read More
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 Excerpt from the Press Release: DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE)…
Read More
ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends Excerpt from the Press Release: DOYLESTOWN, Pa.–(BUSINESS WIRE)–Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and…
Read More
BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured Pipeline is at an exciting inflection point with 20 near-term milestones…
Read More
Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies Excerpt from the Press Release: SAN DIEGO, June 18, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat…
Read More
Combination of World Leading Epitranscriptomics and AI-Driven Automation Aims to Accelerate Development of Cancer Therapies That Halt Metastasis Excerpt from the Press Release: MENLO PARK, Calif. and CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) — Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant therapies, today announced…
Read More
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study Excerpt from the Press Release: MENLO PARK, Calif., June 18, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from…
Read More Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced successful dosing of the first participants in its Phase 1 trial of CPTX2309, Capstan’s lead anti-CD19 in vivo CAR-T candidate, for the…
Read More